Resistance of Lenvatinib in Hepatocellular Carcinoma

Area of Science:

• Oncology
• Pharmacology
• Hepatology

Background:

• Lenvatinib, a multikinase inhibitor, is approved for advanced hepatocellular carcinoma (HCC) treatment.
• It demonstrates superior efficacy over sorafenib, offering higher objective response rates (ORR) and improved progression-free survival (PFS).
• Increasing Lenvatinib resistance necessitates understanding its mechanisms and developing counter-strategies.

Approach:

• This review synthesizes current research on Lenvatinib's mechanisms of action in liver cancer.
• It investigates the molecular and cellular factors contributing to Lenvatinib resistance.
• The review also explores emerging strategies and therapeutic approaches to overcome resistance.

Key Points:

• Lenvatinib inhibits tumor angiogenesis and proliferation in HCC.
• Mechanisms of resistance include alterations in signaling pathways and tumor microenvironment changes.
• Strategies to overcome resistance involve combination therapies and targeting resistance pathways.

Conclusions:

• Lenvatinib remains a vital first-line treatment for advanced HCC.
• Addressing Lenvatinib resistance is critical for sustained therapeutic benefit.
• Further research into resistance mechanisms will guide the development of more effective treatment protocols for HCC.